Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) dropped 5.2% on Friday . The stock traded as low as $10.26 and last traded at $10.23. Approximately 174,259 shares changed hands during mid-day trading, a decline of 88% from the average daily volume of 1,430,290 shares. The stock had previously closed at $10.79.
Ginkgo Bioworks Stock Down 6.5%
The company has a market capitalization of $590.63 million, a PE ratio of -1.10 and a beta of 1.48. The company has a 50-day moving average price of $8.64 and a two-hundred day moving average price of $9.14.
Ginkgo Bioworks (NYSE:DNA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.35). The company had revenue of $48.32 million during the quarter, compared to analysts' expectations of $38.70 million. Ginkgo Bioworks had a negative net margin of 198.84% and a negative return on equity of 52.35%. As a group, equities analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current fiscal year.
Institutional Investors Weigh In On Ginkgo Bioworks
Several hedge funds have recently added to or reduced their stakes in DNA. SBI Securities Co. Ltd. purchased a new stake in Ginkgo Bioworks during the 4th quarter valued at $29,000. US Bancorp DE raised its holdings in Ginkgo Bioworks by 43.5% in the 1st quarter. US Bancorp DE now owns 6,302 shares of the company's stock worth $36,000 after purchasing an additional 1,911 shares during the period. KLP Kapitalforvaltning AS bought a new stake in Ginkgo Bioworks during the fourth quarter valued at about $46,000. CWM LLC raised its stake in Ginkgo Bioworks by 667.6% during the 1st quarter. CWM LLC now owns 12,274 shares of the company's stock valued at $70,000 after purchasing an additional 10,675 shares during the period. Finally, Fox Run Management L.L.C. bought a new stake in Ginkgo Bioworks during the 1st quarter valued at approximately $76,000. Institutional investors own 78.63% of the company's stock.
Ginkgo Bioworks Company Profile
(
Get Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
